Symbols / XENE Stock $56.65 +0.44% Xenon Pharmaceuticals Inc.
XENE (Stock) Chart
About
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Stock Fundamentals
Scroll to Statements| Market Cap | 5.41B | Enterprise Value | 4.17B | Income | -345.91M | Sales | 7.50M | Book/sh | 7.27 | Cash/sh | 6.60 |
| Dividend Yield | — | Payout | 0.00% | Employees | 358 | IPO | — | P/E | — | Forward P/E | -11.97 |
| PEG | — | P/S | 720.79 | P/B | 7.79 | P/C | — | EV/EBITDA | -11.26 | EV/Sales | 556.24 |
| Quick Ratio | 13.17 | Current Ratio | 13.41 | Debt/Eq | 1.37 | LT Debt/Eq | — | EPS (ttm) | -4.36 | EPS next Y | -4.73 |
| EPS Growth | — | Revenue Growth | — | Earnings | 2026-05-11 | ROA | -32.58% | ROE | -51.76% | ROIC | — |
| Gross Margin | 0.00% | Oper. Margin | -49.74% | Profit Margin | 0.00% | Shs Outstand | 95.43M | Shs Float | 78.36M | Short Float | 5.55% |
| Short Ratio | 2.13 | Short Interest | — | 52W High | 63.95 | 52W Low | 28.19 | Beta | 0.74 | Avg Volume | 1.36M |
| Volume | 703.11K | Target Price | $79.24 | Recom | Strong_buy | Prev Close | $56.40 | Price | $56.65 | Change | 0.44% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-16 | main | Wedbush | Outperform → Outperform | $63 |
| 2026-03-10 | main | Wells Fargo | Overweight → Overweight | $68 |
| 2026-03-10 | main | Wedbush | Outperform → Outperform | $64 |
| 2026-03-10 | main | Deutsche Bank | Buy → Buy | $90 |
| 2026-03-10 | main | HC Wainwright & Co. | Buy → Buy | $74 |
| 2026-03-09 | main | Needham | Buy → Buy | $80 |
| 2026-03-09 | main | Baird | Outperform → Outperform | $97 |
| 2026-02-27 | main | Needham | Buy → Buy | $58 |
| 2026-02-27 | main | Wells Fargo | Overweight → Overweight | $49 |
| 2026-02-24 | init | Wolfe Research | — → Outperform | $60 |
| 2026-01-09 | main | JP Morgan | Overweight → Overweight | $62 |
| 2025-12-11 | main | Wells Fargo | Overweight → Overweight | $48 |
| 2025-11-18 | main | JP Morgan | Overweight → Overweight | $60 |
| 2025-11-04 | main | RBC Capital | Outperform → Outperform | $58 |
| 2025-11-04 | main | Wells Fargo | Overweight → Overweight | $44 |
| 2025-11-04 | reit | Needham | Buy → Buy | $55 |
| 2025-10-07 | main | Chardan Capital | Buy → Buy | $55 |
| 2025-09-02 | reit | RBC Capital | Outperform → Outperform | $55 |
| 2025-08-12 | main | Chardan Capital | Buy → Buy | $55 |
| 2025-08-12 | main | RBC Capital | Outperform → Outperform | $55 |
- Xenon's Phase 3 Supports A 'Buy' Despite Its Premium (NASDAQ:XENE) - Seeking Alpha Wed, 22 Apr 2026 20
- Xenon Pharmaceuticals (XENE) 2026 proxy details board elections and new equity plan - Stock Titan Wed, 22 Apr 2026 20
- What Xenon Pharmaceuticals (XENE)'s Positive Phase 3 X-TOLE2 Epilepsy Data Means For Shareholders - simplywall.st Wed, 22 Apr 2026 06
- 5 Best 52-Week High US Stocks to Buy - Insider Monkey hu, 23 Apr 2026 04
- XENE Stock Up as Azetukalner Meets Goal in Focal Onset Seizures Study - Yahoo Finance ue, 10 Mar 2026 07
- Xenon Pharmaceuticals (XENE) Reports Positive Phase 3 Study Resu - GuruFocus Mon, 20 Apr 2026 10
- Will Xenon (XENE) Stock Outperform S&P 500 | Price at $58.45, Up 1.59% - Viral Trades - Cổng thông tin điện tử tỉnh Lào Cai hu, 09 Apr 2026 07
- Xenon Pharmaceuticals surges 43.6% as Phase 3 azetukalner epilepsy data beats expectations - Quiver Quantitative Mon, 09 Mar 2026 07
- Why This Biotech, Up 47%, Could Spark The Next Buyout Frenzy - Investor's Business Daily Mon, 09 Mar 2026 07
- XENE Stock Rallies 50% On Epilepsy Trial Data, But One Analyst Thinks Rival Biohaven Still Has ‘Room To Differentiate’ - Stocktwits Mon, 09 Mar 2026 07
- Xenon lines up four investor conference presentations in Q2 2026 - Stock Titan Wed, 15 Apr 2026 12
- Assessing Xenon Pharmaceuticals (XENE) Valuation After A Sharp Recent Share Price Surge - Yahoo Finance hu, 12 Mar 2026 07
- Xenon Pharmaceuticals Inc. Prices Upsized Public Offering, Anticipated Gross Proceeds of Approximately $650 Million - Quiver Quantitative Wed, 11 Mar 2026 07
- Assessing Xenon Pharmaceuticals (XENE) Valuation After Strong Recent Share Price Momentum - simplywall.st Sat, 18 Apr 2026 01
- Xenon Pharmaceuticals (XENE) boosts 2025 inducement equity plan share reserve - Stock Titan Mon, 13 Apr 2026 20
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
7.50
|
0.00
|
0.00
-100.00%
|
9.43
|
| Operating Revenue |
|
7.50
|
0.00
|
0.00
-100.00%
|
9.43
|
| Operating Expense |
|
380.57
+36.26%
|
279.30
+30.48%
|
214.05
+54.47%
|
138.58
|
| Research And Development |
|
300.94
+43.04%
|
210.39
+25.60%
|
167.51
+58.38%
|
105.77
|
| Selling General And Administration |
|
79.63
+15.57%
|
68.90
+48.05%
|
46.54
+41.85%
|
32.81
|
| General And Administrative Expense |
|
79.63
+15.57%
|
68.90
+48.05%
|
46.54
+41.85%
|
32.81
|
| Other Gand A |
|
79.63
+15.57%
|
68.90
+48.05%
|
46.54
+41.85%
|
32.81
|
| Total Expenses |
|
380.57
+36.26%
|
279.30
+30.48%
|
214.05
+54.47%
|
138.58
|
| Operating Income |
|
-373.07
-33.57%
|
-279.30
-30.48%
|
-214.05
-65.75%
|
-129.14
|
| Total Operating Income As Reported |
|
-373.07
-33.57%
|
-279.30
-30.48%
|
-214.05
-65.75%
|
-129.14
|
| EBITDA |
|
-370.53
-33.89%
|
-276.74
-30.54%
|
-211.99
-65.96%
|
-127.74
|
| Normalized EBITDA |
|
-371.88
-34.90%
|
-275.67
-27.78%
|
-215.74
-75.52%
|
-122.91
|
| Reconciled Depreciation |
|
2.54
-0.66%
|
2.56
+24.21%
|
2.06
+46.69%
|
1.41
|
| EBIT |
|
-373.07
-33.57%
|
-279.30
-30.48%
|
-214.05
-65.75%
|
-129.14
|
| Total Unusual Items |
|
1.35
+226.69%
|
-1.06
-128.38%
|
3.75
+177.70%
|
-4.83
|
| Total Unusual Items Excluding Goodwill |
|
1.35
+226.69%
|
-1.06
-128.38%
|
3.75
+177.70%
|
-4.83
|
| Special Income Charges |
|
—
|
—
|
—
|
0.00
|
| Net Income |
|
-345.91
-47.62%
|
-234.33
-28.48%
|
-182.39
-45.48%
|
-125.37
|
| Pretax Income |
|
-344.89
-44.66%
|
-238.42
-30.51%
|
-182.69
-45.85%
|
-125.25
|
| Net Non Operating Interest Income Expense |
|
26.83
-36.04%
|
41.94
+51.86%
|
27.62
+217.00%
|
8.71
|
| Interest Expense Non Operating |
|
—
|
—
|
—
|
0.00
|
| Net Interest Income |
|
26.83
-36.04%
|
41.94
+51.86%
|
27.62
+217.00%
|
8.71
|
| Interest Expense |
|
—
|
—
|
—
|
0.00
|
| Interest Income Non Operating |
|
26.83
-36.04%
|
41.94
+51.86%
|
27.62
+217.00%
|
8.71
|
| Interest Income |
|
26.83
-36.04%
|
41.94
+51.86%
|
27.62
+217.00%
|
8.71
|
| Other Income Expense |
|
1.35
+226.69%
|
-1.06
-128.38%
|
3.75
+177.70%
|
-4.83
|
| Gain On Sale Of Security |
|
1.35
+226.69%
|
-1.06
-128.38%
|
3.75
+177.70%
|
-4.83
|
| Tax Provision |
|
1.02
+124.85%
|
-4.09
-1300.34%
|
-0.29
-347.46%
|
0.12
|
| Tax Rate For Calcs |
|
0.00
+782.35%
|
0.00
+750.00%
|
0.00
-99.24%
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.20
+1217.87%
|
-0.02
-341.24%
|
0.01
+100.59%
|
-1.26
|
| Net Income Including Noncontrolling Interests |
|
-345.91
-47.62%
|
-234.33
-28.48%
|
-182.39
-45.48%
|
-125.37
|
| Net Income From Continuing Operation Net Minority Interest |
|
-345.91
-47.62%
|
-234.33
-28.48%
|
-182.39
-45.48%
|
-125.37
|
| Net Income From Continuing And Discontinued Operation |
|
-345.91
-47.62%
|
-234.33
-28.48%
|
-182.39
-45.48%
|
-125.37
|
| Net Income Continuous Operations |
|
-345.91
-47.62%
|
-234.33
-28.48%
|
-182.39
-45.48%
|
-125.37
|
| Normalized Income |
|
-347.06
-48.77%
|
-233.28
-25.33%
|
-186.13
-52.80%
|
-121.81
|
| Net Income Common Stockholders |
|
-345.91
-47.62%
|
-234.33
-28.48%
|
-182.39
-45.99%
|
-124.94
|
| Diluted EPS |
|
-4.36
-44.85%
|
-3.01
-10.26%
|
-2.73
-32.52%
|
-2.06
|
| Basic EPS |
|
-4.36
-44.85%
|
-3.01
-10.26%
|
-2.73
-32.52%
|
-2.06
|
| Basic Average Shares |
|
79.25
+1.74%
|
77.89
+16.45%
|
66.89
+10.48%
|
60.54
|
| Diluted Average Shares |
|
79.25
+1.74%
|
77.89
+16.45%
|
66.89
+10.48%
|
60.54
|
| Diluted NI Availto Com Stockholders |
|
-345.91
-47.62%
|
-234.33
-28.48%
|
-182.39
-45.99%
|
-124.94
|
| Preferred Stock Dividends |
|
—
|
—
|
—
|
-0.44
|
| Line Item | Trend | 2023-12-31 |
|---|---|---|
| Total Assets |
|
964.80
|
| Current Assets |
|
644.96
|
| Cash Cash Equivalents And Short Term Investments |
|
638.08
|
| Cash And Cash Equivalents |
|
148.64
|
| Other Short Term Investments |
|
489.44
|
| Receivables |
|
0.87
|
| Accounts Receivable |
|
0.87
|
| Prepaid Assets |
|
—
|
| Other Current Assets |
|
6.01
|
| Total Non Current Assets |
|
319.84
|
| Net PPE |
|
18.85
|
| Gross PPE |
|
30.10
|
| Accumulated Depreciation |
|
-11.25
|
| Properties |
|
0.00
|
| Buildings And Improvements |
|
9.19
|
| Machinery Furniture Equipment |
|
2.77
|
| Other Properties |
|
9.11
|
| Leases |
|
9.02
|
| Investments And Advances |
|
292.79
|
| Non Current Deferred Assets |
|
0.80
|
| Non Current Deferred Taxes Assets |
|
0.80
|
| Non Current Prepaid Assets |
|
7.40
|
| Total Liabilities Net Minority Interest |
|
36.88
|
| Current Liabilities |
|
27.27
|
| Payables And Accrued Expenses |
|
18.55
|
| Payables |
|
8.95
|
| Accounts Payable |
|
8.60
|
| Current Accrued Expenses |
|
9.60
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
7.42
|
| Total Tax Payable |
|
0.35
|
| Current Debt And Capital Lease Obligation |
|
1.30
|
| Current Capital Lease Obligation |
|
1.30
|
| Current Deferred Liabilities |
|
—
|
| Current Deferred Revenue |
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
9.60
|
| Long Term Debt And Capital Lease Obligation |
|
9.60
|
| Long Term Capital Lease Obligation |
|
9.60
|
| Other Non Current Liabilities |
|
—
|
| Stockholders Equity |
|
927.92
|
| Common Stock Equity |
|
927.92
|
| Capital Stock |
|
1,436.37
|
| Common Stock |
|
1,436.37
|
| Preferred Stock |
|
—
|
| Share Issued |
|
75.37
|
| Ordinary Shares Number |
|
75.37
|
| Treasury Shares Number |
|
0.00
|
| Additional Paid In Capital |
|
156.76
|
| Retained Earnings |
|
-665.14
|
| Gains Losses Not Affecting Retained Earnings |
|
-0.08
|
| Other Equity Adjustments |
|
-0.08
|
| Total Equity Gross Minority Interest |
|
927.92
|
| Total Capitalization |
|
927.92
|
| Working Capital |
|
617.69
|
| Invested Capital |
|
927.92
|
| Total Debt |
|
10.90
|
| Capital Lease Obligations |
|
10.90
|
| Net Tangible Assets |
|
927.92
|
| Tangible Book Value |
|
927.92
|
| Available For Sale Securities |
|
292.79
|
| Investmentin Financial Assets |
|
292.79
|
| Preferred Stock Equity |
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-279.12
-53.88%
|
-181.39
-20.04%
|
-151.11
-49.57%
|
-101.03
|
| Cash Flow From Continuing Operating Activities |
|
-279.12
-53.88%
|
-181.39
-20.04%
|
-151.11
-49.57%
|
-101.03
|
| Net Income From Continuing Operations |
|
-345.91
-47.62%
|
-234.33
-28.48%
|
-182.39
-45.48%
|
-125.37
|
| Depreciation Amortization Depletion |
|
2.54
-0.66%
|
2.56
+24.21%
|
2.06
+46.69%
|
1.41
|
| Depreciation |
|
2.54
-0.66%
|
2.56
+24.21%
|
2.06
+46.69%
|
1.41
|
| Depreciation And Amortization |
|
2.54
-0.66%
|
2.56
+24.21%
|
2.06
+46.69%
|
1.41
|
| Other Non Cash Items |
|
1.31
+4.70%
|
1.25
+3.38%
|
1.21
+48.11%
|
0.82
|
| Stock Based Compensation |
|
53.71
+5.90%
|
50.72
+56.67%
|
32.37
+58.87%
|
20.38
|
| Deferred Tax |
|
-3.20
+63.92%
|
-8.86
-2935.62%
|
-0.29
-563.64%
|
-0.04
|
| Deferred Income Tax |
|
-3.20
+63.92%
|
-8.86
-2935.62%
|
-0.29
-563.64%
|
-0.04
|
| Operating Gains Losses |
|
0.70
-6.31%
|
0.74
+216.41%
|
-0.64
-123.45%
|
2.73
|
| Gain Loss On Investment Securities |
|
0.62
|
—
|
—
|
2.93
|
| Unrealized Gain Loss On Investment Securities |
|
0.00
|
0.00
+100.00%
|
-3.55
-221.00%
|
2.93
|
| Net Foreign Currency Exchange Gain Loss |
|
0.07
-90.20%
|
0.74
+216.41%
|
-0.64
-123.45%
|
2.73
|
| Change In Working Capital |
|
4.36
-23.68%
|
5.71
-3.20%
|
5.90
+562.54%
|
-1.28
|
| Change In Receivables |
|
0.10
+116.94%
|
-0.61
-572.31%
|
0.13
-92.60%
|
1.76
|
| Changes In Account Receivables |
|
0.10
+116.94%
|
-0.61
-572.31%
|
0.13
-92.60%
|
1.76
|
| Change In Prepaid Assets |
|
-3.16
-220.83%
|
-0.98
-162.52%
|
1.57
+115.00%
|
-10.49
|
| Change In Payables And Accrued Expense |
|
5.51
-35.40%
|
8.53
+117.02%
|
3.93
-51.24%
|
8.06
|
| Change In Other Working Capital |
|
—
|
—
|
—
|
—
|
| Change In Other Current Liabilities |
|
1.90
+255.90%
|
-1.22
-556.93%
|
0.27
+144.50%
|
-0.60
|
| Investing Cash Flow |
|
218.00
+32.12%
|
165.00
+248.13%
|
-111.39
+62.04%
|
-293.40
|
| Cash Flow From Continuing Investing Activities |
|
218.00
+32.12%
|
165.00
+248.13%
|
-111.39
+62.04%
|
-293.40
|
| Net PPE Purchase And Sale |
|
-0.80
+74.02%
|
-3.08
+45.26%
|
-5.62
-94.09%
|
-2.89
|
| Purchase Of PPE |
|
-0.80
+74.02%
|
-3.08
+45.26%
|
-5.62
-94.09%
|
-2.89
|
| Capital Expenditure |
|
-0.80
+74.02%
|
-3.08
+45.26%
|
-5.62
-94.09%
|
-2.89
|
| Net Investment Purchase And Sale |
|
218.80
+30.18%
|
168.07
+258.91%
|
-105.77
+63.59%
|
-290.51
|
| Purchase Of Investment |
|
-355.66
+33.18%
|
-532.27
+32.96%
|
-793.91
-44.05%
|
-551.14
|
| Sale Of Investment |
|
574.45
-17.98%
|
700.34
+1.77%
|
688.14
+164.03%
|
260.63
|
| Financing Cash Flow |
|
117.11
+865.48%
|
12.13
-96.57%
|
353.52
+26.95%
|
278.47
|
| Cash Flow From Continuing Financing Activities |
|
117.11
+865.48%
|
12.13
-96.57%
|
353.52
+26.95%
|
278.47
|
| Net Issuance Payments Of Debt |
|
—
|
—
|
—
|
0.00
|
| Repayment Of Debt |
|
—
|
—
|
—
|
0.00
|
| Long Term Debt Payments |
|
—
|
—
|
—
|
0.00
|
| Net Long Term Debt Issuance |
|
—
|
—
|
—
|
0.00
|
| Net Common Stock Issuance |
|
112.15
+828.17%
|
12.08
-96.58%
|
353.49
+27.26%
|
277.77
|
| Proceeds From Stock Option Exercised |
|
4.96
+10457.45%
|
0.05
+34.29%
|
0.04
-95.04%
|
0.70
|
| Changes In Cash |
|
55.99
+1414.70%
|
-4.26
-104.68%
|
91.03
+178.50%
|
-115.96
|
| Effect Of Exchange Rate Changes |
|
0.46
+127.39%
|
-1.67
-544.68%
|
0.38
+115.14%
|
-2.48
|
| Beginning Cash Position |
|
142.71
-3.99%
|
148.64
+159.67%
|
57.24
-67.42%
|
175.69
|
| End Cash Position |
|
199.16
+39.56%
|
142.71
-3.99%
|
148.64
+159.67%
|
57.24
|
| Free Cash Flow |
|
-279.92
-51.75%
|
-184.46
-17.70%
|
-156.73
-50.81%
|
-103.92
|
| Interest Paid Supplemental Data |
|
—
|
—
|
—
|
0.00
|
| Amortization Of Securities |
|
7.37
+803.06%
|
0.82
+114.11%
|
-5.79
-122.67%
|
-2.60
|
| Common Stock Issuance |
|
112.15
+828.17%
|
12.08
-96.58%
|
353.49
+27.26%
|
277.77
|
| Issuance Of Capital Stock |
|
112.15
+828.17%
|
12.08
-96.58%
|
353.49
+27.26%
|
277.77
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-04-13 View
- 42026-03-13 View
- 42026-03-13 View
- 42026-03-13 View
- 8-K2026-03-13 View
- 8-K2026-03-12 View
- 42026-03-11 View
- 42026-03-11 View
- 42026-03-11 View
- 8-K2026-03-09 View
- 8-K2026-02-27 View
- 10-K2026-02-26 View
- 8-K2026-02-26 View
- 42026-01-09 View
- 42026-01-09 View
- 42026-01-09 View
- 42026-01-09 View
- 42026-01-02 View
- 42025-12-09 View
- 42025-12-03 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|